Clinical Trials Browser

Enrolling by invitation × ibrutinib × 90 days × Clear all

NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant